Skip to main content
IRLA
NASDAQ Life Sciences

IRulya Posts $27.7M Q3 Loss, Says $105.2M Cash Funds Operations Through 2028

Tom Rudovsky · Reported by Wiseek News
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$39.78
Mkt Cap
$431.274M
52W Low
$15.1
52W High
$909.98
52W Position info
163% above low
Off High info
96% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

IRLA has more than doubled off its 52-week low of $15.1 on elevated volume (2.6× avg).

Summary

IRulya reported a Q3 2026 net loss of $27.7M, or $2.31 per share, versus $13.4M and $49.83 per share a year earlier. Cash and investments stood at $105.2M at September 30, 2026, which the company says funds operations through the end of 2028. R&D fell to $5.9M from $8.1M as eDSP program costs dropped $6.9M, partly offset by $3.8M higher LAM-001 costs, while G&A jumped to $9.0M from $3.3M on $3.0M of post-acquisition fees and one-time severance and retention bonuses. The runway covers multiple planned Phase 2 readouts, with BOS Phase 2 data anticipated in Q1 2027. The widened loss and higher G&A are the main blemishes on an otherwise adequate cash position for a company this size.

At the time of this announcement, IRLA was trading at $39.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $431.3M. The 52-week trading range was $15.10 to $909.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

IRLA - Latest Insights